Silverback Raises $78.5m To Test Localized Therapy Delivered Systemically In Patients

The company will initiate a clinical trial this year for lead ADC candidate SBT6050, which links a HER2-targeting antibody to a TLR8 agonist to activate myeloid cells in the tumor and spur an immune response. 

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
Silverback has raised more than $125m to date • Source: Shutterstock

With $78.5m in series B venture capital, Silverback Therapeutics Inc. will begin its first clinical trial later this year to determine whether its lead antibody-drug conjugate (ADC) SBT6050, which links a HER2-targeted antibody with a TLR8 agonist, will duplicate the company’s preclinical results that showed the ADC provided potent activation of myeloid cells and reprogrammed the tumor microenvironment.

Silverback has now raised more than $125m to date, including a series A extension that brought its initial funding round...

More from Financing

More from Business